Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study
Background Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT) over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer, and relevant guidelines for these patients are lacking. Methods Data on...
Gespeichert in:
| Veröffentlicht in: | Cancer 2025-01, Vol.131 (1), p.e35581-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | e35581 |
| container_title | Cancer |
| container_volume | 131 |
| creator | Wang, Xuelian Shang, Yuhang Zhang, Jiayang Liu, Jiangwei Fang, Zhengbo Liu, Yansong Cheng, Weilun Duan, Yunqiang Hu, Anbang Zhang, Jiarui Li, Mingcui Li, Yanling Zhang, Hanyu Rong, Zhiyuan S. Shakila, Suborna Kong, Fanjing Guo, Baoliang |
| description | Background
Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT) over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer, and relevant guidelines for these patients are lacking.
Methods
Data on patients with T1cN0M0‐stage HER2+ breast cancer who received chemotherapy and surgery were extracted from 2010 to 2020 from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM) was used to create well‐balanced cohorts for the NAT and AT groups. Kaplan–Meier (KM) analysis and Cox proportional hazards models were used to assess the differences between NAT and AT in terms of overall survival (OS) and breast cancer–specific survival (BCSS). Additionally, logistic regression models were used to explore factors associated with response to NAT.
Results
After PSM, 2140 patient pairs were successfully matched, which achieved a balanced distribution between the NAT and AT groups. KM curves revealed similar OS and BCSS between patients receiving NAT and those undergoing AT. A multivariate Cox model identified achieving pathological complete response (pCR) after NAT, compared with AT, as a protective prognostic factor for OS (hazard ratio, 0.52; 95% CI, 0.35–0.77; p |
| doi_str_mv | 10.1002/cncr.35581 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3107785935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3107785935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2461-8a3e183f3467ec152841880d424da94bff61d4a52aa080fb27178199ef467463</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEokNhwwOgK7FBaFLs2PnrrhoNP1IFUpkFu8hxbmY8SuxgxxnNro-AxBt2x1vgMKULFiws-15_99wjnSh6SckFJSR5J7W0FyxNC_ooWlBS5jGhPHkcLQghRZxy9u0seubcPpR5krKn0RkrGcmyMltEv756O6lJdGD8KE2PDkwLGo1o9n4SeoQJrfMOHupxh1YMR1AaBjEq1KODgxp3sKFyCdo0eHf7Q-M2_E24hJ3vhQYcVIO2D2u21hwC3Ao5GgsWJQ7zI7m7_TkYp-YhqC0KN4IUWqK9hCuYTaLqurmxhPUs1ivTme1xCUI3sA7nBp3vgpfBDL4Ly40OPmrhsAE3-ub4PHrSis7hi_v7PNq8X29WH-PrLx8-ra6uY5nwjMaFYEgL1jKe5ShpmhScFgVpeMIbUfK6bTPacJEmQpCCtHWS07ygZYltGOAZO4_enGQHa757dGPVKydx9o7Gu4pRkudFWrI0oK__QffGWx3MBSoNJmiSkUC9PVHSGucsttVgVS_ssaKkmvOv5vyrP_kH-NW9pK97bB7Qv4EHgJ6Ag-rw-B-pavV5dXMS_Q2g68Ko</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3151831260</pqid></control><display><type>article</type><title>Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wang, Xuelian ; Shang, Yuhang ; Zhang, Jiayang ; Liu, Jiangwei ; Fang, Zhengbo ; Liu, Yansong ; Cheng, Weilun ; Duan, Yunqiang ; Hu, Anbang ; Zhang, Jiarui ; Li, Mingcui ; Li, Yanling ; Zhang, Hanyu ; Rong, Zhiyuan ; S. Shakila, Suborna ; Kong, Fanjing ; Guo, Baoliang</creator><creatorcontrib>Wang, Xuelian ; Shang, Yuhang ; Zhang, Jiayang ; Liu, Jiangwei ; Fang, Zhengbo ; Liu, Yansong ; Cheng, Weilun ; Duan, Yunqiang ; Hu, Anbang ; Zhang, Jiarui ; Li, Mingcui ; Li, Yanling ; Zhang, Hanyu ; Rong, Zhiyuan ; S. Shakila, Suborna ; Kong, Fanjing ; Guo, Baoliang</creatorcontrib><description>Background
Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT) over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer, and relevant guidelines for these patients are lacking.
Methods
Data on patients with T1cN0M0‐stage HER2+ breast cancer who received chemotherapy and surgery were extracted from 2010 to 2020 from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM) was used to create well‐balanced cohorts for the NAT and AT groups. Kaplan–Meier (KM) analysis and Cox proportional hazards models were used to assess the differences between NAT and AT in terms of overall survival (OS) and breast cancer–specific survival (BCSS). Additionally, logistic regression models were used to explore factors associated with response to NAT.
Results
After PSM, 2140 patient pairs were successfully matched, which achieved a balanced distribution between the NAT and AT groups. KM curves revealed similar OS and BCSS between patients receiving NAT and those undergoing AT. A multivariate Cox model identified achieving pathological complete response (pCR) after NAT, compared with AT, as a protective prognostic factor for OS (hazard ratio, 0.52; 95% CI, 0.35–0.77; p < .001) and BCSS (hazard ratio, 0.60; 95% CI, 0.37–0.98; p = .041). A logistic regression model revealed that White race and hormone receptor–negative status independently predicted pCR.
Conclusions
For patients with T1cN0M0‐stage HER2+ breast cancer, NAT demonstrated comparable OS and BCSS to AT. Patients who achieved pCR after NAT exhibited significantly better survival outcomes compared with those who received AT.
In a retrospective cohort study of 8768 patients with T1cN0M0‐stage human epidermal growth factor receptor 2–positive breast cancer, neoadjuvant therapy demonstrated similar overall survival and breast cancer–specific survival compared with adjuvant therapy. Achieving pathological complete response after neoadjuvant therapy was associated with significantly better survival outcomes than those receiving adjuvant therapy, which supports its routine use for these patients.</description><identifier>ISSN: 0008-543X</identifier><identifier>ISSN: 1097-0142</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.35581</identifier><identifier>PMID: 39306696</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adjuvant therapy ; Adult ; Aged ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; early‐stage breast cancer ; Epidemiology ; Epidermal growth factor ; ErbB-2 protein ; Female ; Growth factors ; Hazard assessment ; human epidermal growth factor receptor 2–positive (HER2+) ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Population studies ; Receptor, ErbB-2 - metabolism ; Receptors ; Regression analysis ; Regression models ; SEER Program ; Statistical models ; Surveillance ; Surveillance, Epidemiology, and End Results (SEER) ; Survival ; survival outcomes</subject><ispartof>Cancer, 2025-01, Vol.131 (1), p.e35581-n/a</ispartof><rights>2024 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2461-8a3e183f3467ec152841880d424da94bff61d4a52aa080fb27178199ef467463</cites><orcidid>0000-0002-4022-6739</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.35581$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.35581$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39306696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xuelian</creatorcontrib><creatorcontrib>Shang, Yuhang</creatorcontrib><creatorcontrib>Zhang, Jiayang</creatorcontrib><creatorcontrib>Liu, Jiangwei</creatorcontrib><creatorcontrib>Fang, Zhengbo</creatorcontrib><creatorcontrib>Liu, Yansong</creatorcontrib><creatorcontrib>Cheng, Weilun</creatorcontrib><creatorcontrib>Duan, Yunqiang</creatorcontrib><creatorcontrib>Hu, Anbang</creatorcontrib><creatorcontrib>Zhang, Jiarui</creatorcontrib><creatorcontrib>Li, Mingcui</creatorcontrib><creatorcontrib>Li, Yanling</creatorcontrib><creatorcontrib>Zhang, Hanyu</creatorcontrib><creatorcontrib>Rong, Zhiyuan</creatorcontrib><creatorcontrib>S. Shakila, Suborna</creatorcontrib><creatorcontrib>Kong, Fanjing</creatorcontrib><creatorcontrib>Guo, Baoliang</creatorcontrib><title>Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT) over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer, and relevant guidelines for these patients are lacking.
Methods
Data on patients with T1cN0M0‐stage HER2+ breast cancer who received chemotherapy and surgery were extracted from 2010 to 2020 from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM) was used to create well‐balanced cohorts for the NAT and AT groups. Kaplan–Meier (KM) analysis and Cox proportional hazards models were used to assess the differences between NAT and AT in terms of overall survival (OS) and breast cancer–specific survival (BCSS). Additionally, logistic regression models were used to explore factors associated with response to NAT.
Results
After PSM, 2140 patient pairs were successfully matched, which achieved a balanced distribution between the NAT and AT groups. KM curves revealed similar OS and BCSS between patients receiving NAT and those undergoing AT. A multivariate Cox model identified achieving pathological complete response (pCR) after NAT, compared with AT, as a protective prognostic factor for OS (hazard ratio, 0.52; 95% CI, 0.35–0.77; p < .001) and BCSS (hazard ratio, 0.60; 95% CI, 0.37–0.98; p = .041). A logistic regression model revealed that White race and hormone receptor–negative status independently predicted pCR.
Conclusions
For patients with T1cN0M0‐stage HER2+ breast cancer, NAT demonstrated comparable OS and BCSS to AT. Patients who achieved pCR after NAT exhibited significantly better survival outcomes compared with those who received AT.
In a retrospective cohort study of 8768 patients with T1cN0M0‐stage human epidermal growth factor receptor 2–positive breast cancer, neoadjuvant therapy demonstrated similar overall survival and breast cancer–specific survival compared with adjuvant therapy. Achieving pathological complete response after neoadjuvant therapy was associated with significantly better survival outcomes than those receiving adjuvant therapy, which supports its routine use for these patients.</description><subject>Adjuvant therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>early‐stage breast cancer</subject><subject>Epidemiology</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Growth factors</subject><subject>Hazard assessment</subject><subject>human epidermal growth factor receptor 2–positive (HER2+)</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Population studies</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>SEER Program</subject><subject>Statistical models</subject><subject>Surveillance</subject><subject>Surveillance, Epidemiology, and End Results (SEER)</subject><subject>Survival</subject><subject>survival outcomes</subject><issn>0008-543X</issn><issn>1097-0142</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEokNhwwOgK7FBaFLs2PnrrhoNP1IFUpkFu8hxbmY8SuxgxxnNro-AxBt2x1vgMKULFiws-15_99wjnSh6SckFJSR5J7W0FyxNC_ooWlBS5jGhPHkcLQghRZxy9u0seubcPpR5krKn0RkrGcmyMltEv756O6lJdGD8KE2PDkwLGo1o9n4SeoQJrfMOHupxh1YMR1AaBjEq1KODgxp3sKFyCdo0eHf7Q-M2_E24hJ3vhQYcVIO2D2u21hwC3Ao5GgsWJQ7zI7m7_TkYp-YhqC0KN4IUWqK9hCuYTaLqurmxhPUs1ivTme1xCUI3sA7nBp3vgpfBDL4Ly40OPmrhsAE3-ub4PHrSis7hi_v7PNq8X29WH-PrLx8-ra6uY5nwjMaFYEgL1jKe5ShpmhScFgVpeMIbUfK6bTPacJEmQpCCtHWS07ygZYltGOAZO4_enGQHa757dGPVKydx9o7Gu4pRkudFWrI0oK__QffGWx3MBSoNJmiSkUC9PVHSGucsttVgVS_ssaKkmvOv5vyrP_kH-NW9pK97bB7Qv4EHgJ6Ag-rw-B-pavV5dXMS_Q2g68Ko</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Wang, Xuelian</creator><creator>Shang, Yuhang</creator><creator>Zhang, Jiayang</creator><creator>Liu, Jiangwei</creator><creator>Fang, Zhengbo</creator><creator>Liu, Yansong</creator><creator>Cheng, Weilun</creator><creator>Duan, Yunqiang</creator><creator>Hu, Anbang</creator><creator>Zhang, Jiarui</creator><creator>Li, Mingcui</creator><creator>Li, Yanling</creator><creator>Zhang, Hanyu</creator><creator>Rong, Zhiyuan</creator><creator>S. Shakila, Suborna</creator><creator>Kong, Fanjing</creator><creator>Guo, Baoliang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4022-6739</orcidid></search><sort><creationdate>20250101</creationdate><title>Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study</title><author>Wang, Xuelian ; Shang, Yuhang ; Zhang, Jiayang ; Liu, Jiangwei ; Fang, Zhengbo ; Liu, Yansong ; Cheng, Weilun ; Duan, Yunqiang ; Hu, Anbang ; Zhang, Jiarui ; Li, Mingcui ; Li, Yanling ; Zhang, Hanyu ; Rong, Zhiyuan ; S. Shakila, Suborna ; Kong, Fanjing ; Guo, Baoliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2461-8a3e183f3467ec152841880d424da94bff61d4a52aa080fb27178199ef467463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adjuvant therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>early‐stage breast cancer</topic><topic>Epidemiology</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Growth factors</topic><topic>Hazard assessment</topic><topic>human epidermal growth factor receptor 2–positive (HER2+)</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Population studies</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>SEER Program</topic><topic>Statistical models</topic><topic>Surveillance</topic><topic>Surveillance, Epidemiology, and End Results (SEER)</topic><topic>Survival</topic><topic>survival outcomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xuelian</creatorcontrib><creatorcontrib>Shang, Yuhang</creatorcontrib><creatorcontrib>Zhang, Jiayang</creatorcontrib><creatorcontrib>Liu, Jiangwei</creatorcontrib><creatorcontrib>Fang, Zhengbo</creatorcontrib><creatorcontrib>Liu, Yansong</creatorcontrib><creatorcontrib>Cheng, Weilun</creatorcontrib><creatorcontrib>Duan, Yunqiang</creatorcontrib><creatorcontrib>Hu, Anbang</creatorcontrib><creatorcontrib>Zhang, Jiarui</creatorcontrib><creatorcontrib>Li, Mingcui</creatorcontrib><creatorcontrib>Li, Yanling</creatorcontrib><creatorcontrib>Zhang, Hanyu</creatorcontrib><creatorcontrib>Rong, Zhiyuan</creatorcontrib><creatorcontrib>S. Shakila, Suborna</creatorcontrib><creatorcontrib>Kong, Fanjing</creatorcontrib><creatorcontrib>Guo, Baoliang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xuelian</au><au>Shang, Yuhang</au><au>Zhang, Jiayang</au><au>Liu, Jiangwei</au><au>Fang, Zhengbo</au><au>Liu, Yansong</au><au>Cheng, Weilun</au><au>Duan, Yunqiang</au><au>Hu, Anbang</au><au>Zhang, Jiarui</au><au>Li, Mingcui</au><au>Li, Yanling</au><au>Zhang, Hanyu</au><au>Rong, Zhiyuan</au><au>S. Shakila, Suborna</au><au>Kong, Fanjing</au><au>Guo, Baoliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>131</volume><issue>1</issue><spage>e35581</spage><epage>n/a</epage><pages>e35581-n/a</pages><issn>0008-543X</issn><issn>1097-0142</issn><eissn>1097-0142</eissn><abstract>Background
Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT) over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer, and relevant guidelines for these patients are lacking.
Methods
Data on patients with T1cN0M0‐stage HER2+ breast cancer who received chemotherapy and surgery were extracted from 2010 to 2020 from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM) was used to create well‐balanced cohorts for the NAT and AT groups. Kaplan–Meier (KM) analysis and Cox proportional hazards models were used to assess the differences between NAT and AT in terms of overall survival (OS) and breast cancer–specific survival (BCSS). Additionally, logistic regression models were used to explore factors associated with response to NAT.
Results
After PSM, 2140 patient pairs were successfully matched, which achieved a balanced distribution between the NAT and AT groups. KM curves revealed similar OS and BCSS between patients receiving NAT and those undergoing AT. A multivariate Cox model identified achieving pathological complete response (pCR) after NAT, compared with AT, as a protective prognostic factor for OS (hazard ratio, 0.52; 95% CI, 0.35–0.77; p < .001) and BCSS (hazard ratio, 0.60; 95% CI, 0.37–0.98; p = .041). A logistic regression model revealed that White race and hormone receptor–negative status independently predicted pCR.
Conclusions
For patients with T1cN0M0‐stage HER2+ breast cancer, NAT demonstrated comparable OS and BCSS to AT. Patients who achieved pCR after NAT exhibited significantly better survival outcomes compared with those who received AT.
In a retrospective cohort study of 8768 patients with T1cN0M0‐stage human epidermal growth factor receptor 2–positive breast cancer, neoadjuvant therapy demonstrated similar overall survival and breast cancer–specific survival compared with adjuvant therapy. Achieving pathological complete response after neoadjuvant therapy was associated with significantly better survival outcomes than those receiving adjuvant therapy, which supports its routine use for these patients.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39306696</pmid><doi>10.1002/cncr.35581</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4022-6739</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2025-01, Vol.131 (1), p.e35581-n/a |
| issn | 0008-543X 1097-0142 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3107785935 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adjuvant therapy Adult Aged Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer therapies Chemotherapy Chemotherapy, Adjuvant early‐stage breast cancer Epidemiology Epidermal growth factor ErbB-2 protein Female Growth factors Hazard assessment human epidermal growth factor receptor 2–positive (HER2+) Humans Kaplan-Meier Estimate Middle Aged Neoadjuvant Therapy Neoplasm Staging Population studies Receptor, ErbB-2 - metabolism Receptors Regression analysis Regression models SEER Program Statistical models Surveillance Surveillance, Epidemiology, and End Results (SEER) Survival survival outcomes |
| title | Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A34%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20outcomes%20of%20neoadjuvant%20versus%20adjuvant%20therapy%20in%20patients%20with%20T1c,%20node%E2%80%90negative,%20human%20epidermal%20growth%20factor%20receptor%202%E2%80%93positive%20breast%20cancer:%20A%20Surveillance,%20Epidemiology,%20and%20End%20Results%20population%E2%80%90based%20study&rft.jtitle=Cancer&rft.au=Wang,%20Xuelian&rft.date=2025-01-01&rft.volume=131&rft.issue=1&rft.spage=e35581&rft.epage=n/a&rft.pages=e35581-n/a&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.35581&rft_dat=%3Cproquest_cross%3E3107785935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3151831260&rft_id=info:pmid/39306696&rfr_iscdi=true |